Patient-Derived Cell Lines Improve Clinical Relevance

Patient-derived human primary cell-based assays are developed from either tissue, blood from healthy donors or with defined disease characteristics to predict translational clinical relevance. Over the years, Charles River has established a network of collaborators to access patient-derived cells across numerous therapeutic areas such as Fibrosis and Oncology.

Patient-derived cell-based assays provide clinically relevant data.

Scientific Poster entitled two in vitro assays relevant to lung fibrosis for evaluating the potency and efficacy of prospective anti-fibrotic drugs. A comparison of compounds with claimed antifibrotic activity in two novel human primary cell-based assays using IPF derived patient material

Download Now

Integrating patient-derived cells into translational research

  • CRISPR/Cas9 editing capabilities combining these patient-derived cells with our CRISPR/Cas9 platform allows generation of the most relevant cell systems; those with mutations, reporters, or isogenic controls
  • Biochemical and functional cell-based assays to mimic the diseased cellular environment
  • High-content imaging screening and profiling platforms disease state insight at the subcellular
  • Therapeutic area applications scientific expertise in for more than 20 disease indications
  • Mechanism of action studies using adenoviral SilenceSelect® and FLeXSelect® libraries
  • Protein (Luminex, MesoScale) and RNA (qPCR, digital droplet PCR, and NGS) readouts

RNA Fluorescence In Situ Hybridization by High-Content Imaging

RNA Fluorescence In Situ Hybridization by High-Content Imaging.

Ask Us a Question

Patient-Derived Cells - Frequently Asked Questions (FAQ’s)